Somatropin Deficiency, clinically known as Growth Hormone Deficiency (GHD), is a recognized endocrine condition characterized by insufficient secretion of the growth hormone somatropin from the pituitary gland. In adults, this deficiency can lead to a constellation of symptoms including reduced muscle mass, increased visceral adiposity, diminished bone density, and impaired psychological well-being. Identifying and treating this deficiency is crucial for mitigating the associated decline in metabolic and physical function, which often mirrors accelerated aging.
Origin
The term is derived from ‘somatropin,’ the clinical name for the human growth hormone, and ‘deficiency,’ indicating a lack or shortage. The recognition of adult GHD as a distinct clinical syndrome, separate from childhood growth failure, developed with the ability to measure the hormone accurately and the advent of recombinant human growth hormone for replacement therapy.
Mechanism
Somatropin is released in a pulsatile manner, primarily during deep sleep, and its main function is to stimulate the liver to produce Insulin-like Growth Factor 1 (IGF-1). The deficiency mechanism involves a failure in the hypothalamic-pituitary axis to generate adequate somatropin pulses, resulting in low circulating IGF-1 levels. This lack of downstream signaling impairs cellular anabolism, lipid metabolism, and tissue repair, contributing significantly to a compromised physiological state.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.